Robert Clarke (Kinaset)
November 30, 2020 07:03 AM ESTUpdated 11:14 AM
Financing
Startups

Ki­naset launch­es with $40M and a JAK in­hibitor from Vec­tura's old pipeline

Nicole DeFeudis

Editor

Ki­naset Ther­a­peu­tics is join­ing the search for a bet­ter se­vere asth­ma treat­ment, pick­ing up where Vec­tura left off when it de­cid­ed to clear house last …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

A service from the Financial Times